CN110123770A - A kind of Eliquis pharmaceutical composition and preparation method thereof - Google Patents
A kind of Eliquis pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN110123770A CN110123770A CN201910536815.4A CN201910536815A CN110123770A CN 110123770 A CN110123770 A CN 110123770A CN 201910536815 A CN201910536815 A CN 201910536815A CN 110123770 A CN110123770 A CN 110123770A
- Authority
- CN
- China
- Prior art keywords
- added
- eliquis
- wet
- polyvinylpyrrolidone
- preferred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of Eliquis pharmaceutical composition and preparation method thereof.The present invention provides a kind of Eliquis tablet and preparation method, which is prepared by the supplementary material of following weight degree: Eliquis 10%, filler 70%, disintegrating agent 15%, adhesive 2%, lubricant 1.5%, surface ionic active agent 1.5%.This product uses wet granulation technology, and preparation process is simple, easily operated, favorable reproducibility, suitable for large-scale industrialized production, and the dissolution of gained Eliquis tablet is fast, stability is high and low to bulk pharmaceutical chemicals Particle size requirements.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of solid composite of Eliquis and preparation method thereof.
Background technique
Eliquis (Apixaban) is a kind of anticoagulant blood products of Bristol Myers Squibb Yu Pfizer's cooperative research and development, for selecting
The prevention of phase hip joint or replacement knee in arthroplasty adult patient Venous Thrombosis.Eliquis is in March, 2011 in European Union batch
Quasi- listing, and obtain FDA in December, 2012 and ratify the medicine in U.S.'s listing, acquisition China national food and medicine supervision pipe in 2013
Import drug permit that reason office issues and in Discussion on Chinese Listed.
Bristol-Myers Squibb company discloses Ah piperazine in the world patent WO2003/049681 disclosed in 2003
The synthetic method of husky class.Wherein Eliquis is the known compound having following structure:
Bristol-Myers Squibb company and the world patent WO2006078331 disclosed on July 27th, 2006
In, a kind of method for crystallising of open Eliquis；It is disclosed in world patent WO2007022165 disclosed on October 18th, 2007
The cyclodextrin complexes prescription of Eliquis；The prescription patent WO2011106478 of on September 1st, 2011 open Eliquis；
The liquid preparation patent WO2014052678 of on September 26th, 2013 open Eliquis.World patent WO2011106478 is disclosed
The Eliquis preparation that is prepared using wet granulation method and using greater particle size pharmaceutical preparation cause it is not satisfactory
Exposure, this may bring quality control challenge.It further discloses the dry granulation method for being used to prepare composition, and described group
Closing object includes the crystallization Eliquis particle for being equal to or less than about 89 μm by the D90 of laser defusing measure.Chinese patent
CN104095823 discloses a kind of preparation method of Eliquis tablet, it is disclosed that a kind of label of Apixaban tablet by
Eliquis, lactose, microcrystalline cellulose, croscarmellose sodium, dodecyl sodium sulfate, hard magnesium are made, preparation
Method, which uses, will be added direct tablet compressing after other auxiliary materials mix, the Ah piperazine of the preparation after Eliquis and lactose co-grinding first
Husky class's piece dissolution 15min is just able to achieve dissolution rate and averagely reaches greater than 80%, is just able to achieve dissolution rate average out to after dissolving out 30min
To 90% or more, dissolution rate is slow, and impurity content is more.Therefore that there is an urgent need to develop a kind of pair of Particle size requirements is low, stability is high
With the Eliquis solid composite for realizing Fast Stripping.
Summary of the invention
Eliquis composition, which has, in the prior art dissolves out small, stability difference and the disadvantage high to Particle size requirements, from
And it is more demanding to production of raw medicine, technique requirement is increasingly complex, is unsuitable for industrialized production.The present invention passes through research discovery
A kind of stability is high, dissolves out the fast and Eliquis composition and preparation method thereof low to bulk pharmaceutical chemicals Particle size requirements.
One aspect of the present invention provides a kind of pharmaceutical composition of Eliquis, forms as follows:
A kind of Eliquis tablet, label are made of Eliquis and pharmaceutic adjuvant, wherein pharmaceutic adjuvant be filler,
One of disintegrating agent, adhesive, lubricant, surfactant are a variety of.
Eliquis tablet is prepared by the supplementary material of following weight percentage: Eliquis 1%~10%, filler
50%~75%, disintegrating agent 10%~30%, adhesive 1%~10%, lubricant 1%~5%, surface ionic active agent
0.5%~1.5%.
Preferred scheme is Eliquis 3%~10%, filler 55%~75%, disintegrating agent 10%~25%, bonding
Agent 2%~8%, lubricant 1%~3%, surface ionic active agent 1%~1.5%.
Further preferred scheme is, Eliquis 5%~10%, filler 55%~70%, disintegrating agent 15%~
25%, adhesive 2%~6%, lubricant 1.5%~2.5%, surface ionic active agent 1.2%~1.5%.
Scheme still more preferably is Eliquis 10%, filler 70%, disintegrating agent 15%, adhesive 2%, profit
Lubrication prescription 1.5%, surface ionic active agent 1.5%.
Wherein the filler is selected from Lactis Anhydrous, microcrystalline cellulose, mannitol, pregelatinized starch, calcium monohydrogen phosphate, sulfuric acid
One of calcium, calcium carbonate, sorbierite or cornstarch are a variety of；It is preferred that Lactis Anhydrous, microcrystalline cellulose, mannitol, phosphoric acid
One of hydrogen calcium, sorbierite or cornstarch are a variety of；In further preferred microcrystalline cellulose, calcium monohydrogen phosphate or cornstarch
It is one or more；
The disintegrating agent is selected from croscarmellose sodium, sodium carboxymethyl starch, hydroxypropyl cellulose, crospovidone
Or one of dried starch or a variety of；It is preferred that one of sodium carboxymethyl starch, hydroxypropyl cellulose, crospovidone or more
Kind；Further preferred one or both of sodium carboxymethyl starch or crospovidone；
Described adhesive is selected from hydroxypropylcellulose, methylcellulose, carmethose, polyvinylpyrrolidone, poly- second
One of glycol or hydroxypropyl methylcellulose are a variety of；It is preferred that methylcellulose, carmethose or polyvinylpyrrolidone
In it is one or more；Further preferred one or both of methylcellulose or polyvinylpyrrolidone；
It is sweet that the lubricant is selected from stearic acid, magnesium stearate, talcum powder, superfine silica gel powder, tristerin or behenic acid
One of grease is a variety of；It is preferred that one of magnesium stearate, tristerin or Compritol 888 ATO or a variety of；Into one
Walk one or both of preferred magnesium stearate or Compritol 888 ATO；
The surfactant is selected from one of dodecyl sodium sulfate, Tween 80 or poloxamer or a variety of；It is preferred that
Tween 80.
Wherein, the filler preferably microcrystalline cellulose and two kinds of calcium monohydrogen phosphate, and microcrystalline cellulose: calcium monohydrogen phosphate
Weight percent is 3:1-1:1；It is preferred that 2:1-1:1；Further preferred 1.8:1.
The specific prescription of Eliquis tablet is Eliquis 1%~10%, microcrystalline cellulose 35%~45%, phosphoric acid
Hydrogen calcium 15%~30%, sodium carboxymethyl starch 10%~30%, polyvinylpyrrolidone 1%~10%, Compritol 888 ATO 1%
~5%, Tween 80 0.5%~1.5%；
Preferred scheme is, Eliquis 3%~10%, microcrystalline cellulose 40%~45%, calcium monohydrogen phosphate 15%~
30%, sodium carboxymethyl starch 10%~25%, polyvinylpyrrolidone 2%~8%, Compritol 888 ATO 1%~3%, tween
80 1%~1.5%；
Further preferred scheme is Eliquis 5%~10%, microcrystalline cellulose 35%~45%, calcium monohydrogen phosphate
20%~25%, sodium carboxymethyl starch 15%~25%, polyvinylpyrrolidone 2%~6%, Compritol 888 ATO 1.5%~
2.5%, Tween 80 1.2%~1.5%；
Scheme still more preferably is Eliquis 10%, microcrystalline cellulose 45%, calcium monohydrogen phosphate 25%, carboxymethyl
Sodium starch 15%, polyvinylpyrrolidone 2%, Compritol 888 ATO 1.5%, Tween 80 1.5%；
Another object of the present invention is to provide a kind of preparation methods of Eliquis tablet being adapted with aforementioned schemes.
It is described the preparation method is as follows:
(1) adhesive is added to the water, stirring and dissolving；
(2) Eliquis, filler, disintegrating agent, surfactant are stirred；
(3) adhesive is added in step (2), whole grain, mix lubricant, tabletting is added in granulation；
It (4) optionally, further include coating steps.
Preferred scheme are as follows:
(1) polyvinylpyrrolidone is added to the water, stirring and dissolving；
(2) recipe quantity Eliquis, microcrystalline cellulose, calcium monohydrogen phosphate, sodium carboxymethyl starch, Tween 80 addition whole grain is wet
In method mixer-granulator, it is stirred；
(3) polyvinylpyrrolidone is added in the wet mixing pelletizer in (2)；
(4) wet granular in (3) is subjected to wet granulation；
(5) wet granular obtained by step (4) is added in fluid bed granulator after wet whole grain and is dried；
(6) optionally, intermediate obtained by step (5) is added in pelletizing machine and carries out whole grain；
(7) intermediate obtained by step (6) is added in hopper mixing machine, Compritol 888 ATO is added and is mixed；
(8) tabletting in tablet press machine is added in intermediate obtained by step (7), prepares label；
(9) optionally, film coating is carried out with label of the film coating to step (8)；
Wherein, coating weight gain is 2.0%~2.5%.
Further preferred scheme are as follows:
(1) by polyvinylpyrrolidone sieving for standby；
(2) polyvinylpyrrolidone is added to the water, stirring and dissolving to clear；
(3) recipe quantity Eliquis, microcrystalline cellulose, calcium monohydrogen phosphate, sodium carboxymethyl starch, Tween 80 addition whole grain is wet
In method mixer-granulator, it is stirred；
(4) polyvinylpyrrolidone is added in the wet granulator in (3)；
(5) wet granular in (4) is subjected to wet granulation, low speed granulation: rotating speed of agitator 120rpm, granulating cutter revolving speed
1200rpm, pelletize 120s；High speed is pelletized: rotating speed of agitator 175rpm, granulating cutter revolving speed 1800rpm, and pelletize 60s；
(6) wet granular obtained by step (5) is added in fluid bed granulator after wet whole grain and is dried, drying temperature 45
DEG C, moisture control≤4.00%；
(7) intermediate obtained by step (6) is added in pelletizing machine and carries out whole grain, pelletizing machine revolving speed is 300~450rpm；
(8) intermediate obtained by step (7) is added in hopper mixing machine, Compritol 888 ATO is added and is mixed；
(9) tabletting in tablet press machine is added in intermediate obtained by step (8), control plain piece hardness is respectively as follows: 0.1g specification:
10.00~13.00kgf, 0.3g specification: 12.00~16.00kgf；
(10) optionally, intermediate obtained by step (9) being added in seed-coating machine and will be coated, control coating weight gain is 2.0%~
2.5%.
Specific embodiment
In order to further illustrate the present invention, the present invention is specifically addressed below in conjunction with specific embodiment, but this hair
Bright protection scope is not limited to specific embodiment.
Dissolution medium: sample is dissolved in 2 type dissolving device of United States Pharmacopeia (USP), in the mixing speed of 75rpm, 37 ±
At a temperature of 0.5 DEG C, carried out in 6.8 phosphate buffer of 900mL pH containing 0.05%SLS.
1 filler type of embodiment is investigated
It is the stream of microcrystalline cellulose, calcium monohydrogen phosphate, pregelatinized starch and calcium carbonate to particle that filler is investigated in the above experiment
The influence of dynamic property, friability and dissolution rate, the results showed that the flowing of particle when filler is microcrystalline cellulose and calcium monohydrogen phosphate
Property is good, friability is small, dissolves out.
2 filler ratio of embodiment is investigated
The mobility of particle can be made to be deteriorated it can be seen from the above result that microcrystalline cellulose ratio increases or reduces, friability becomes
Greatly, and result of extraction is deteriorated.Therefore, preferable flowing is able to achieve when microcrystalline cellulose and calcium monohydrogen phosphate ratio are 1:1-3:1
Property, lesser friability and quickly dissolution.
Embodiment 3: disintegrating agent type is investigated
It is sodium carboxymethyl starch, crospovidone, croscarmellose sodium and Gan Dian that disintegrating agent is investigated in the above experiment
Influence of the powder to the mobility of particle, friability and dissolution rate, the results showed that when disintegrating agent is that sodium carboxymethyl starch and crosslinking are poly-
Good fluidity, the friability of particle are small when tieing up ketone, and dissolution is fast.
Embodiment 4: lubricant type is investigated
It is Compritol 888 ATO, superfine silica gel powder, talcum powder and tristerin to particle that lubricant is investigated in the above experiment
Mobility, friability and dissolution rate influence, the results showed that when lubricant be Compritol 888 ATO when particle good fluidity,
Friability is small, and dissolution is fast.
The confirmation of 5 prescription of embodiment
Operating procedure:
(1) that polyvinylpyrrolidone is crossed 60 sieves is spare；
(2) polyvinylpyrrolidone is added to the water, stirring and dissolving to clear；
(3) by recipe quantity Eliquis (partial size be 120 μm), microcrystalline cellulose, calcium monohydrogen phosphate, sodium carboxymethyl starch, spit
Temperature 80 is added in whole grain wet mixing pelletizer, rotating speed of agitator 120rpm, mixes 900s；
(4) polyvinylpyrrolidone is added in the wet granulator in (3), rotating speed of agitator 10rpm, wriggling revolution speed
500rpm；
(5) wet granular in (4) is subjected to wet granulation, low speed granulation: rotating speed of agitator 120rpm, granulating cutter revolving speed
1200rpm, pelletize 120s；High speed is pelletized: rotating speed of agitator 175rpm, granulating cutter revolving speed 1800rpm, and pelletize 60s；
(6) wet granular obtained by step (5) is added in fluid bed granulator after wet whole grain and is dried, drying temperature 45
DEG C, moisture control≤4.00%；
(7) intermediate obtained by step (6) is added in pelletizing machine and carries out whole grain, pelletizing machine revolving speed is 300~450rpm；
(8) intermediate obtained by step (7) is added in hopper mixing machine, Compritol 888 ATO is added and is mixed, mixes
Machine revolving speed is 15rpm, mixes 10min；
(9) tabletting in tablet press machine is added in intermediate obtained by step (8), control plain piece hardness is respectively as follows: 0.1g:10.00
~13.00kgf, 0.3g:12.00~16.00kgf；
(10) optionally, intermediate obtained by step (9) being added in seed-coating machine and will be coated, control coating weight gain is 2.0%~
2.5%.
6 Eliquis tablet stability test of embodiment:
(1) 0.1g specification piece in embodiment 5 is placed in 60 DEG C of high temperature, 25 DEG C/RH92.5%, (total illumination is or not illumination
Lower than 1.2 × 106Luxhr it under the conditions of), is sampled respectively at 5d, 10d, detection, compared with 0d, test result is as follows:
(2) by embodiment 5 0.1g specification piece place 40 DEG C of ± 2 DEG C/RH75% ± 5% under the conditions of, respectively at 1M,
2M, 3M, 6M sample detection, and compared with 0M result, test result is as follows:
(3) by embodiment 5 0.1g specification piece place 30 DEG C of ± 2 DEG C/RH 65% ± 5% under the conditions of, respectively at 3M,
6M, 9M sample detection, and compared with 0M result, test result is as follows:
It can be seen from the above result that pharmaceutical composition of the invention is in influence factor, acceleration and long-term stable experiment process
In in relation to substance, dissolution rate, content results significant change is had no compared with 0d/0M.To illustrate Ah piperazine provided by the present invention
Husky class's piece is more stable.
Claims (8)
1. a kind of Eliquis tablet, which is characterized in that the tablet includes filler, and filler is microcrystalline cellulose and phosphoric acid
Hydrogen calcium.
2. Eliquis tablet according to claim 1, which is characterized in that the microcrystalline cellulose: calcium monohydrogen phosphate weight
Amount percentage is 3:1-1:1；It is preferred that 2:1-1:1；Further preferred 1.8:1.
3. Eliquis tablet according to claim 1, which is characterized in that prepared by the supplementary material of following weight percentage
It forms:
It is preferred that:
It is further preferred:
It is more preferable:
4. Eliquis tablet according to claim 3, which is characterized in that
The disintegrating agent is selected from croscarmellose sodium, sodium carboxymethyl starch, hydroxypropyl cellulose, crospovidone or dry
One of starch is a variety of；It is preferred that one of sodium carboxymethyl starch, hydroxypropyl cellulose or crospovidone or a variety of；Into
One or both of the preferred sodium carboxymethyl starch of one step or crospovidone；
Described adhesive is selected from hydroxypropylcellulose, methylcellulose, carmethose, polyvinylpyrrolidone, polyethylene glycol
Or one of hydroxypropyl methylcellulose or a variety of；It is preferred that one in methylcellulose, carmethose or polyvinylpyrrolidone
Kind is a variety of；Further preferred one or both of methylcellulose or polyvinylpyrrolidone；
The lubricant is selected from stearic acid, magnesium stearate, talcum powder, superfine silica gel powder, tristerin or Compritol 888 ATO
One of or it is a variety of；It is preferred that one of magnesium stearate, tristerin or Compritol 888 ATO or a variety of；It is further excellent
Select one or both of magnesium stearate or Compritol 888 ATO；
The surfactant is selected from one of dodecyl sodium sulfate, Tween 80 or poloxamer or a variety of；It is preferred that tween
80。
5. Eliquis tablet according to any one of claims 1-4, which is characterized in that the Eliquis tablet
Composition are as follows:
It is preferred that:
It is further preferred:
It is more preferable:
6. the method for preparing Eliquis tablet described in claim 1-5 any one, the specific steps of which are as follows:
(1) adhesive is added to the water, stirring and dissolving；
(2) Eliquis, filler, disintegrating agent, surfactant are stirred；
(3) adhesive is added in step (2), whole grain, mix lubricant, tabletting is added in granulation；
It (4) optionally, further include coating steps.
7. according to the method described in claim 6, it is characterized in that, specific step is as follows:
(1) polyvinylpyrrolidone is added to the water, stirring and dissolving；
(2) recipe quantity Eliquis, microcrystalline cellulose, calcium monohydrogen phosphate, sodium carboxymethyl starch, Tween 80 are added whole grain wet process and mixed
It closes in granulator, is stirred；
(3) polyvinylpyrrolidone is added in the wet mixing pelletizer in (2)；
(4) wet granular in (3) is subjected to wet granulation；
(5) wet granular obtained by step (4) is added in fluid bed granulator after wet whole grain and is dried；
(6) optionally, intermediate obtained by step (5) is added in pelletizing machine and carries out whole grain；
(7) intermediate obtained by step (6) is added in hopper mixing machine, Compritol 888 ATO is added and is mixed；
(8) tabletting in tablet press machine is added in intermediate obtained by step (7), prepares label；
(9) optionally, film coating is carried out with label of the film coating to step (8)；
Wherein, coating weight gain is 2.0%~2.5%.
8. the method according to the description of claim 7 is characterized in that the specific steps of which are as follows:
(1) by polyvinylpyrrolidone sieving for standby；
(2) polyvinylpyrrolidone is added to the water, stirring and dissolving to clear；
(3) recipe quantity Eliquis, microcrystalline cellulose, calcium monohydrogen phosphate, sodium carboxymethyl starch, Tween 80 are added whole grain wet process and mixed
It closes in granulator, is stirred；
(4) polyvinylpyrrolidone is added in the wet granulator in (3)；
(5) wet granular in (4) is subjected to wet granulation, low speed granulation: rotating speed of agitator 120rpm, granulating cutter revolving speed 1200rpm,
Pelletize 120s；High speed is pelletized: rotating speed of agitator 175rpm, granulating cutter revolving speed 1800rpm, and pelletize 60s；
(6) wet granular obtained by step (5) being added in fluid bed granulator after wet whole grain and is dried, drying temperature is 45 DEG C,
Moisture control≤4.00%；
(7) intermediate obtained by step (6) is added in pelletizing machine and carries out whole grain, pelletizing machine revolving speed is 300~450rpm；
(8) intermediate obtained by step (7) is added in hopper mixing machine, Compritol 888 ATO is added and is mixed；
(9) intermediate obtained by step (8) is added tabletting in tablet press machine, control plain piece hardness is respectively as follows: 0.1g specification: 10.00
~13.00kgf, 0.3g specification: 12.00~16.00kgf；
(10) optionally, intermediate obtained by step (9) being added in seed-coating machine and will be coated, control coating weight gain is 2.0%~
2.5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910536815.4A CN110123770A (en) | 2019-06-20 | 2019-06-20 | A kind of Eliquis pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910536815.4A CN110123770A (en) | 2019-06-20 | 2019-06-20 | A kind of Eliquis pharmaceutical composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110123770A true CN110123770A (en) | 2019-08-16 |
Family
ID=67578791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910536815.4A Pending CN110123770A (en) | 2019-06-20 | 2019-06-20 | A kind of Eliquis pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110123770A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113041227A (en) * | 2021-03-03 | 2021-06-29 | 河北常山生化药业股份有限公司 | Apixaban tablet and preparation method thereof |
| WO2022150029A1 (en) * | 2021-01-08 | 2022-07-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet comprising apixaban |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017182908A1 (en) * | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
| CN109464415A (en) * | 2019-01-09 | 2019-03-15 | 江苏豪森药业集团有限公司 | Eliquis pharmaceutical composition and preparation method thereof |
-
2019
- 2019-06-20 CN CN201910536815.4A patent/CN110123770A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017182908A1 (en) * | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
| CN109464415A (en) * | 2019-01-09 | 2019-03-15 | 江苏豪森药业集团有限公司 | Eliquis pharmaceutical composition and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022150029A1 (en) * | 2021-01-08 | 2022-07-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet comprising apixaban |
| CN113041227A (en) * | 2021-03-03 | 2021-06-29 | 河北常山生化药业股份有限公司 | Apixaban tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103459430B (en) | The method producing the cellulose derivative with high-bulk-density and good fluidity | |
| CN108472261B (en) | Apixaban solid composition and preparation method thereof | |
| WO2022037544A1 (en) | Medicinal solid preparation of tolvaptan and preparation method therefor | |
| CN110123770A (en) | A kind of Eliquis pharmaceutical composition and preparation method thereof | |
| CN110354086B (en) | Preparation method of candesartan cilexetil tablets | |
| CN104997778A (en) | Olmesartan medoxomil and amlodipine medicinal composition | |
| CN108078944A (en) | Solid composite containing ticagrelor and preparation method thereof | |
| CN110755392B (en) | Rivaroxaban tablet pharmaceutical composition and preparation method thereof | |
| CN106511288A (en) | Preparation method of febuxostat tablets | |
| CN113662919B (en) | Stable cefixime tablet and preparation method thereof | |
| CN111012753A (en) | Method for improving stability of sodium valproate tablets | |
| CN104098489A (en) | Micronized glibenclamide and composition thereof | |
| CN107744509B (en) | Mosapride citrate tablet and preparation method thereof | |
| CN114681404A (en) | Repaglinide granule pharmaceutical composition and preparation method thereof | |
| CN106580924B (en) | Multi-unit release pharmaceutical composition of amlodipine maleate and preparation method thereof | |
| CN114601812B (en) | Probucol tablet composition and preparation method thereof | |
| CN111358795A (en) | Tofacitinib citrate preparation and preparation method thereof | |
| CN114099506B (en) | Pharmaceutical composition containing sorafenib | |
| CN115554255B (en) | High-stability folic acid tablet and preparation method thereof | |
| CN113768889B (en) | Cilostazol-containing pharmaceutical composition and preparation method thereof | |
| CN111214442B (en) | Apixaban co-micropowder | |
| CN104352468A (en) | Preparation method of olanzapine tablet highly dissolved out in vitro in pH range of 5.5-7.0 | |
| CN106913545B (en) | Glimepiride tablet and preparation method thereof | |
| CN115554247A (en) | Repaglinide granules | |
| CN113842367A (en) | Cannabidiol premix and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190816 |
|
| WD01 | Invention patent application deemed withdrawn after publication |